- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Time to talk to adults with rheumatic diseases about herpes zoster vaccination. (Pubmed Central) - Mar 22, 2024 Moreover, a recombinant herpes zoster vaccine (Shingrix) has become available that can be given to these patients in a more accessible manner than the original live-attenuated vaccine (Zostavax). Here, we evaluate existing evidence on risk factors for herpes zoster and the safety and efficacy of the recombinant vaccine in patients with rheumatic immune-mediated inflammatory diseases and discuss the necessity of herpes zoster vaccination for these patients.
- |||||||||| Dectova (zanamivir) / GSK
Enrollment open, Trial completion date, Trial primary completion date: Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) (clinicaltrials.gov) - Mar 21, 2024 P1, N=74, Recruiting, N=48 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
- |||||||||| Clinical, Retrospective data, Review: Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 21, 2024
This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents.
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial completion date, Trial primary completion date: KOSMOS: Kesimpta (clinicaltrials.gov) - Mar 21, 2024 P=N/A, N=149, Recruiting, While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents. Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
- |||||||||| mizagliflozin (VGX-3235) / Vogenx
Enrollment closed, Trial completion date, Trial primary completion date, Adverse events: Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions (clinicaltrials.gov) - Mar 21, 2024 P2, N=15, Active, not recruiting, Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> May 2024
- |||||||||| abiraterone acetate / Generic mfg.
Clinical, Journal, Metastases: Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate. (Pubmed Central) - Mar 19, 2024 The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear...Use of BMAs was defined as the administration of bisphosphonates and denosumab within 90 days before and after randomization...Zoledronic acid was the most frequently administered BMA in both the AAP (93 [70.5%]) and the ADT (88 [67.2%]) cohorts...No evidence was found that the outcomes of BMA varied by AAP or ADT (hazard ratio for time to SRE, 0.99 [95% CI, 0.48-2.08]; P?=?.99 for interaction; hazard ratio for OS, 1.31 [95% CI, 0.88-1.96]; P?=?.18 for interaction). The findings of this cohort study suggest that use of BMAs was associated with a longer time to SRE in patients with high-risk mCSPC treated with ADT, with or without AAP, suggesting that BMA use might provide benefits to this population.
- |||||||||| Xenical (orlistat) / Roche, GSK, denifanstat (TVB-2640) / Sagimet Biosci
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Checkpoint block: FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma. (Pubmed Central) - Mar 19, 2024 The identification of FASN as a negative regulator of MHC-I provides the rationale for combining FASN inhibitors and immunotherapy for treating HCC. Inhibition of FASN increases MHC-I protein levels by suppressing its palmitoylation and lysosomal degradation, which stimulates immune activity against hepatocellular carcinoma and enhances the efficacy of immune checkpoint inhibition.
- |||||||||| Review, Journal: Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches. (Pubmed Central) - Mar 19, 2024
Foscarnet, cidofovir, and maribavir are treatments for refractory or resistant-CMV. Selection of CMV antiviral treatment should be determined by patient-specific factors, including severity of illness, resistant or refractory disease, dose-limiting adverse effects, and the preferred route of administration.
- |||||||||| GSK2330811 / GSK
Journal: Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. (Pubmed Central) - Mar 19, 2024 We utilized clinical data from studies of an anti-OSM monoclonal antibody (GSK2330811) in healthy volunteers (n?=?49) and systemic sclerosis patients (n?=?35), to quantitatively determine the link between OSM and alterations in red blood cell (RBC) and platelet production...Individual extent of RBC precursor modulation was moderately correlated to skin mRNA gene expression changes. The physiological basis and consideration of interplay among hematopoietic variables makes the model generalizable to other drug and nondrug scenarios, with adaptations for patient populations, diseases, and therapeutics that modulate hematopoiesis or exhibit risk of anemia and/or thrombocytopenia.
- |||||||||| Zejula (niraparib) / GSK, J&J
P3 data, Review, Journal: Progression-free survival and safety at 3.5 (Pubmed Central) - Mar 19, 2024 P3 These results support that niraparib remains an important treatment option to help delay the cancer from coming back or getting worse in patients with newly diagnosed advanced ovarian cancer that responded to initial treatment. Clinical Trial Registration: NCT02655016 (PRIMA study) (ClinicalTrials.gov).
- |||||||||| Promacta (eltrombopag) / Novartis
P2 data, Clinical Trial,Phase II, Journal: Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. (Pubmed Central) - Mar 19, 2024 Number of platelet transfusions received, overall survival, progression-free survival, GVHD rate, relapse rate, and non-relapse mortality were similar between groups. Overall, eltrombopag is safe and improves platelet recovery in patients undergoing haplo-HSCT with bone marrow graft and PCy.
- |||||||||| Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia (clinicaltrials.gov) - Mar 18, 2024 P2, N=15, Recruiting, Niraparib plus AI has encouraging antitumor activity and a manageable safety profile for pts with pretreated AI-resistant HR+/HER2- ABC with gBRCAm, warranting further research of the combination. Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Jun 2024
- |||||||||| Xenical (orlistat) / Roche, GSK
Journal: Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. (Pubmed Central) - Mar 18, 2024 We discovered two of the most potent PPT1 inhibitors reported to date, orlistat (IC50 178.8 nM) and palmostatin B (IC50 11.8 nM)...The combination of in vitro enzymatic and biophysical assays enabled the identification of several molecules that can bind or inhibit PPT1 and may aid in the discovery of modulators or chaperones. The molecules identified could be used as a starting point for further optimization as treatments for other potential therapeutic applications outside CLN1 disease, such as cancer and neurological diseases.
- |||||||||| Beyfortus (nirsevimab) / AstraZeneca, Sanofi, Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK, Abrysvo (PF-06928316) / Pfizer
Review, Journal: Nirsevimab: A Review. (Pubmed Central) - Mar 18, 2024 Eltrombopag appears to be effective, safe and well-tolerated in refractory ITP patients with CTD; larger studies are needed to confirm the generalizability of these findings. In May 2023, the FDA approved 2 vaccines, RSVpreF3 (Arexvy
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Journal: Pain Related to Intradetrusor BotulinumtoxinA: A Randomized Clinical Trial. (Pubmed Central) - Mar 18, 2024 Procedural discomfort related to BTX-A injection for idiopathic OAB was not different between 2 injection protocols. Overall satisfaction was high for both groups, and there was no difference in symptom scores or adverse events.
- |||||||||| trimethoprim/sulfamethoxazole / Generic mfg., Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, nitrofurantoin / Generic mfg.
Journal: Antibiotics for UTI Prevention After Intradetrusor OnabotulinumtoxinA Injections. (Pubmed Central) - Mar 18, 2024 Prophylactic antibiotic choice and duration of treatment potentially affect UTI incidence after in-office, intradetrusor onabotulinumtoxinA injections. Nitrofurantoin and trimethoprim-sulfamethoxazole for 3 days have the lowest UTI incidence.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Comparing Impact of Overactive Bladder Therapies on Nocturia. (Pubmed Central) - Mar 18, 2024 Nitrofurantoin and trimethoprim-sulfamethoxazole for 3 days have the lowest UTI incidence. For women with nocturia ?2/night, treatment with AC, BTX 100 or 200 units, or SNM led to a significant decrease in voids/night at 6 months.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Journal: Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview. (Pubmed Central) - Mar 18, 2024 P3 Co-administration of RZV with routine vaccines does not significantly alter the reactogenicity, immunogenicity or safety of RZV or the co-administered vaccine. Healthcare practitioners should consider routine co-administration of RZV with other adult vaccines to improve vaccination coverage.
|